ArticleClinical immunology (Orlando, Fla.)2026
Vamifeport, a clinical stage oral ferroportin inhibitor, alleviates murine lupus nephritis: A pilot study.
Article in Clinical immunology (Orlando, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Even after immunosuppression, the rate of complete remission for proliferative lupus nephritis (LN) remains around 50%, highlighting the need for identifying novel therapeutic targets. Iron exacerbates LN, and treatment with hepcidin, the primary regulator of systemic iron metabolism, ameliorates LN. This identifies ferroportin, the only known hepcidin receptor, as a target to alleviate LN. Vamifeport is a safe oral ferroportin inhibitor with promising pharmacodynamic effect, currently in clinical development for diseases with dysregulated iron metabolism. We demonstrate that oral vamifeport administration attenuates renal pathology in MRL/lpr mice, independently of circulating autoantibodies and glomerular immune complex deposits. We identified that vamifeport reduces ferroportin expression on monocytes. LN serum-induced inflammation is attenuated only in long-term vamifeport treated monocyte-derived macrophages (MDM), but not in renal proximal tubular epithelial cells (ferroportin-expressing cells in the kidney). Collectively, our study suggests that vamifeport has a high potential to be further developed clinically as an adjunct therapeutic to treat LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.